Short answer
Larimar Therapeutics, Inc. (LRMR) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 8.01 (Other Events). Updated investor slide deck posted March 9, 2026, to be used in ongoing meetings with investors and analysts.
Larimar Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated investor slide deck posted March 9, 2026, to be used in ongoing meetings with investors and analysts
- Substantive content in Exhibit 99.1: presentation likely contains pipeline/clinical updates for Larimar's lead program (nomlabofusp for Friedreich's ataxia)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Larimar Therapeutics, Inc. 8-K filings
Get the next LRMR 8-K as it lands
Follow LRMR for push alerts, or ask the research agent what this filing means.